Home > Journals > Minerva Pneumologica > Past Issues > Minerva Pneumologica 2014 June;53(2) > Minerva Pneumologica 2014 June;53(2):81-3

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA PNEUMOLOGICA

A Journal on Diseases of the Respiratory System


Official Journal of the Italian Society of Thoracic Endoscopy
Indexed/Abstracted in: EMBASE, Scopus, Emerging Sources Citation Index


eTOC

 

REVIEWS  


Minerva Pneumologica 2014 June;53(2):81-3

Copyright © 2014 EDIZIONI MINERVA MEDICA

language: English

N-acetylcysteine and idiopathic pulmonary fibrosis

Rindone E. 1, Rosset L. 2, Carnuccio C. 3

1 Department of Clinical Biological Sciences, Faculty of Medicine and Surgery, San Luigi Gonzaga, University of Turin, Turin, Italy; 2 Faculty of Medicine and Surgery, San Luigi Gonzaga, University of Turin, Turin, Italy; 3 Casa di Cura Villa Serena, Piossasco, Turin, Italy


PDF  


Despite there are a lot of ongoing trials studying drugs for the idiopathic pulmunary fibrosis (IPF) still there is not a cure. By the moment that N-acetylcysteine (NAC)-based therapy is commonly used to treat IPF patients and the results of a 2012 study went in this direction, and finally the PANTHER-IPF study results, regarding the NAC monotherapy arm, are about to be published, we decided to collect and analyze all the data that we could find on PubMed and make a sum of them all. At the end of this work we can strongly recommend further investigation on the NAC monotherapy in IPF patients since different studies give us good results on this direction.

top of page

Publication History

Cite this article as

Corresponding author e-mail